Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Morten Ladekarl

doi:10.21037/cco-23-17

Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Morten Ladekarl^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

1 Citation (Scopus)

22 Downloads (Pure)

Original language	English
Article number	10
Journal	Chinese clinical oncology
Volume	12
Issue number	2
Pages (from-to)	10
Number of pages	1
ISSN	2304-3865
DOIs	https://doi.org/10.21037/cco-23-17
Publication status	Published - Apr 2023

Keywords

Antibodies, Monoclonal, Humanized/pharmacology
Carcinoma, Hepatocellular/drug therapy
Humans
Liver Neoplasms/drug therapy
Sorafenib
pembrolizumab
second line
hepatocellular carcinoma (HCC)
Immune check point inhibitor
randomized study

Access to Document

10.21037/cco-23-17Licence: CC BY-NC-ND 4.0

Ladekarl (2023). Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefitFinal published version, 136 KBLicence: CC BY-NC-ND 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{49cf857278284e7c9c3a8008421c0a1a,

title = "Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?",

keywords = "Antibodies, Monoclonal, Humanized/pharmacology, Carcinoma, Hepatocellular/drug therapy, Humans, Liver Neoplasms/drug therapy, Sorafenib, pembrolizumab, second line, hepatocellular carcinoma (HCC), Immune check point inhibitor, randomized study",

author = "Morten Ladekarl",

year = "2023",

month = apr,

doi = "10.21037/cco-23-17",

language = "English",

volume = "12",

pages = "10",

journal = "Chinese clinical oncology",

issn = "2304-3865",